Glenmark Launches Generic Olanzapine for Injection in the US

Glenmark Pharmaceuticals Inc., USA, a subsidiary of Glenmark Pharmaceuticals Limited, has announced the launch of Olanzapine for Injection, 10 mg/vial, Single-Dose Vial, in the United States.

The newly launched product is bioequivalent and therapeutically equivalent to Zyprexa IntraMuscular Injection, the reference medicine manufactured by Cheplapharm Registration GmbH.

With this launch, Glenmark continues to expand its injectable medicines portfolio while strengthening its position in the institutional healthcare market.

New Generic Option for Healthcare Providers

Olanzapine for Injection is now available as a generic alternative to the branded reference product.

By offering a therapeutically equivalent injectable medicine, Glenmark aims to provide hospitals and healthcare providers with another quality treatment option while helping improve access to more affordable medicines.

The launch also supports the company's broader strategy of increasing its presence in the injectable pharmaceutical segment.

Company Focuses on Institutional Market Growth

According to Marc Kikuchi, President and Business Head, North America, the launch represents an important milestone in Glenmark's growth strategy.

He said the company is focused on building a strong injectables portfolio and expanding its footprint in the institutional channel. He also noted that the launch reflects Glenmark's ongoing commitment to improving patient access to quality and affordable treatment options while meeting the changing needs of healthcare providers.

Glenmark Continues to Strengthen Its Product Portfolio

Glenmark Pharmaceuticals Limited is a global research-led pharmaceutical company with operations across several international markets.

The company develops and manufactures branded medicines, generic pharmaceuticals, innovative therapies, and consumer healthcare products. It also operates manufacturing facilities and research and development centers across multiple continents.

Glenmark continues to focus on key therapeutic areas, including respiratory diseases, dermatology, and oncology, while expanding its portfolio with new product launches in global markets.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!